Cardiovascular disease in survivors of childhood cancer

Neha Bansal, Shahnawaz M. Amdani, Kelley K. Hutchins, Steven E. Lipshultz

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.

Original languageEnglish (US)
Pages (from-to)628-638
Number of pages11
JournalCurrent Opinion in Pediatrics
Volume30
Issue number5
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Keywords

  • Anthracycline
  • Cardio-oncology
  • Cardiotoxicity
  • Childhood cancer
  • Survivorship

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Cardiovascular disease in survivors of childhood cancer'. Together they form a unique fingerprint.

Cite this